Clearing senescent cells rejuvenates aging kidneys in mice

Senescent cells are cells that have stopped dividing but refuse to die. Over time they accumulate in tissues and secrete a cocktail of inflammatory molecules known as the senescence-associated secretory phenotype (SASP). In the aging kidney, SASP contributes to tissue scarring (fibrosis), reduced blood flow, and declining filtration capacity.

In the study, mice received a combination of dasatinib and quercetin every two weeks from twelve months of age for a total of eight months. Dasatinib is a generic cancer drug; quercetin is a plant flavonol available in any supplement store. Together they selectively kill senescent cells, a strategy called senolysis. Treated mice showed fewer senescence markers, reduced kidney fibrosis and restored levels of klotho, a protein that normally declines with age and supports kidney function.

Multiple biological layers measured at once

The study is notable for its use of multi-omics: the researchers combined protein analysis (proteomics) with cell-type-specific gene activity profiling (single-cell transcriptomics) and other readouts. This allowed them to show that treatment not only reduced senescence markers but also restored fatty acid metabolism in kidney cells and normalized excessive cell-to-cell signalling. Untreated aged kidneys displayed overactive communication networks that were largely absent in treated animals.

Promise for humans remains uncertain

The mouse results add to a growing body of animal evidence supporting senolytic treatment for age-related organ decline. Caution is warranted, however. Mouse models do not automatically translate to humans, and optimal dosing and timing for human use remain unknown. Small exploratory human trials have shown promising signals, but large clinical studies are still lacking. Because dasatinib and quercetin are inexpensive off-patent compounds, there is limited commercial incentive to fund the large trials needed to confirm efficacy in people.

From a longevity perspective, the consistency of the evidence is notable. If the findings translate, a periodic low-cost regimen might help protect kidney function in later life. That remains a significant ‘if’, but the direction of the data is encouraging.

Read the original article